Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (238)	10/4/2002 8:03:41 PM
From: nigel bates	Respond to of 469

looks like about seven quarters of burn, first blush It's a little difficult to figure, given the restructuring. I'd guess somewhat less until new compounds hit the clinic, and of course there's Zavesca... Can't see why they didn't deal with CAT (they have a technology collaboration) rather than investing in BioInvent - although things did look a little different back in March. Would have helped conserve cash, and reduced risk.